Compass Pathways Q2 FY26 net loss widens to $253.8 million
CMPS•CMPS•CMPS•CMPS•R&D expense edged down to USD 29.2 million from USD 30.3 million, reflecting lower clinical trial costs as the Phase 3 TRD program nears completion.
G&A expense climbed to USD 23.2 million from USD 12.6 million on higher commercial preparedness spending; cash rose to USD 433.3 million at June 30.
FDA granted rolling NDA submission and review for COMP360 in TRD, with completion targeted for Q4; launch expected in H1 2027, subject to approval and DEA rescheduling.
Compass Pathways posted a Q2 net loss of USD 253.8 million, worsening from USD 38.4 million a year earlier; loss per share widened to USD 1.88 from USD 0.41.
Warrant fair-value adjustment drove results, with a non-cash loss of USD 205.6 million versus USD 2.5 million in Q2 2025.
